Please login to the form below

Not currently logged in
Email:
Password:

influenza

This page shows the latest influenza news and features for those working in and with pharma, biotech and healthcare.

Moderna files record $500m IPO for RNA pipeline

Moderna files record $500m IPO for RNA pipeline

as well as vaccines for viral infections such as respiratory syncytial virus (RSV), influenza, chikungunya and Zika.

Latest news

  • Roche’s new flu pill Xofluza approved in US Roche’s new flu pill Xofluza approved in US

    The treatment has been approved for acute, uncomplicated influenza in people 12 years of age and older, and has been shown to be effective against a wide range of flu viruses, ... The drug is also to be studied in a phase 3 programme including paediatric

  • Encouraging data for Roche flu drug ahead of FDA decision Encouraging data for Roche flu drug ahead of FDA decision

    Trial looks at benefts in high risk groups. Roche has produced promising phase 3 data for its first-in-class influenza treatment in patients who are at a high risk for ... The drug is also to be studied in a phase 3 programme including paediatric

  • Pfizer signs mRNA flu vaccine deal with BioNTech Pfizer signs mRNA flu vaccine deal with BioNTech

    Pfizer has teamed up with German biotech BioNTech to develop a new generation of influenza vaccines that can be made quicker and more cheaply than current products. ... New flu vaccines are needed to provide improved protection against seasonal flu, and

  • Your health is about more than just your health Your health is about more than just your health

    emergency care use, lower use of mammography, lower receipt of influenza vaccine, poorer ability to demonstrate taking medications appropriately, poorer ability to interpret labels and health messages, and, among seniors, poorer

  • Roche’s Tamiflu successor hits the mark in complicated flu Roche’s Tamiflu successor hits the mark in complicated flu

    Baloxavir marboxil met its primary objective and cut flu-related complications. Roche has reported a second pivotal data on a novel influenza drug – baloxavir marboxil – that it says is the first

More from news
Approximately 15 fully matching, plus 179 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2016 Deal Watch February 2016

    coli and influenza, and in toxicology applications. While Abbott already has a significant diagnostics presence with global sales in 2015 in this segment of $4.6bn, it forecasts that the acquisition

  • Another lost decade for research? Another lost decade for research?

    diseases that cause significant morbidity and mortality, such as influenza and malaria, but remain difficult to vaccinate against.

  • Pharma deals in June 2015 Pharma deals in June 2015

    85. BioCryst Pharmaceuticals/ CSL. RAPIVAB (peramivir injection) for the treatment of influenza (marketed).

  • Wearables: the tangible product of the patient revolution Wearables: the tangible product of the patient revolution

    The opportunity is massive - in the public health arena, there exists the possibility that outbreaks of diseases such as Ebola or influenza could be seen and stopped before they become critical.

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    318. Novartis/CSL. Asset purchase. Influenza vaccines. 275. Five Prime/GSK. Expansion of collaboration.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • To track disease, follow the money

    The way that influenza spreads can be tracked by tools such as Flusurvey,(1)  which produces rapidly-updated heatmaps of illness across the country.

  • Influenza

    Agency: BASTARD. LONDON. Product: Self Promotion. Client: Self Promotion. Therapy area: Self Promotion. View the PMHub profile for: BASTARD. LONDON.

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics